Experimental CAR-T therapy shows promise for tough lymphomas
NCT ID NCT04067414
First seen Feb 14, 2026 · Last updated May 19, 2026 · Updated 12 times
Summary
This early-phase study tested a new treatment called BZ019 in 12 adults with certain types of B-cell lymphoma that had stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and see if the therapy could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.